Clinical trials: Islets of Langerhans Transplantation
Type 1 Diabetes, Organ Transplantation
Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
This single center phase 2 clinical trial, is designed for confirming the efficacy and safety of sequential islet allotransplantation with steroid free immunosuppression in patients with previous kidney transplantation.
- Conditions
- Type 1 Diabetes, Organ Transplantation, Immunosuppression
- Trial name
- NCT01123187
- Testing
- islet transplantation
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille
Islet Transplantation
Nephrologic Prognosis 10 Years After Diabetes Cell Therapy
Islet transplantation for type 1 diabetes results are still improving, and actually Insulin-independence with normal HbA1c is obtained in 50% of patients after 5 years, 80% of c-peptide positive patients.
- Trial name
- PRONOCELDIAB (NCT02627690)
- Testing
- islet transplanted, non islet transplanted
- Where
- France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Lille
Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1
Islet Transplant Alone in OMENtum
The study is a phase 2, monocentric, open-label study. The investigators will recruit 12 patients with T1D to be randomly (1:1) assigned to receive islet either into the liver through the portal venous circulation (standard…
- Trial name
- ITA-OMEN (NCT02803905)
- Testing
- Biological: Islet transplantation
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Lorenzo Piemonti
Type 1 Diabetes
Islet Transplantation Using Campath-1H and Infliximab Induction
Islet transplantation has been investigated as a treatment for Type 1 diabetes mellitus in selected patients with inadequate glucose control despite insulin therapy.
- Trial name
- NCT00175266
- Testing
- alemtuzumab, islet transplant, infliximab
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of Alberta
Islets of Langerhans Transplantation
Novel Method of Pancreatic Islet Transplantation Into the Omentum
The investigators propose to conduct a pilot clinical study in 10 type 1 diabetic subjects suffering from hypoglycemia unawareness syndrome and episodes of severe hypoglycemia, in which therapy with transplantation of allogeneic…
- Trial name
- NCT04884633
- Testing
- Pancreatic islet transplantation
- Where
- Czechia
- Volunteers
- 6 people
- Sponsor
- Frantisek Saudek
Type 1 Diabetes, Hypoglycemia
Islet Allotransplantation With Steroid Free Immunosuppression
The restoration of endogenous insulin secretion carries significant hopes for shifting the paradigm of life long exogenous insulin therapy in selected groups of patients with type 1 diabetes(T1D).
- Conditions
- Type 1 Diabetes, Hypoglycemia, Metabolic Diseases
- Trial name
- NCT00446264
- Testing
- islet transplantation, daclizumab - sirolimus - tacrolimus
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille
Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Experimental
hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure
The broad, long-term goal of this proposal is to improve the results and applicability of islet allotransplantation early in the course of type 1 diabetes through the administration of selective and short-term immunotherapy.
- Conditions
- Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Experimental, Transplantation, Homologous, Islets of Langerhans Transplantation
- Trial name
- NCT00008801
- Testing
- hOKT3gamma1 (Ala-ala)
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Type 1 Diabetes Mellitus
Visualizing Beta Cells After Islet Transplantation
In patients with type 1 diabetes (T1D) that have undergone islet of Langerhans transplantation or are on the waiting list for transplantation, Ga-68-exendin PET imaging is performed to study the visualization of transplanted…
- Trial name
- GLP1-transpl (NCT03785236)
- Testing
- 68Ga-NODAGA-exendin PET/CT
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 13 people
- Sponsor
- Radboud University Medical Center
Type1 Diabetes Mellitus, Type2 Diabetes
Circulating Extracellular Vesicles Released by Human Islets of Langerhans
Beta-cells release extracellular vesicles (EV) and exosomes under normal and pathophysiologic conditions. These EV contain beta-cell specific autoantigens which may trigger the immune response at the initiation of type 1…
- Conditions
- Type1 Diabetes Mellitus, Type2 Diabetes, Islet Cell Transplantation
- Trial name
- NCT03106246
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Type 1 Diabetes
ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion.
This study will evaluate the safety and performance of ENCRT-103-hPI, which is a cargo of primary islets inside Encellin's ENC-103-CED.
- Trial name
- NCT07680673
- Testing
- ENCRT-103-hPI encompasses the ENC-103 device, which will be implanted once loaded with primary islet cargo.
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Encellin
Type 1 Diabetes Mellitus
Islet Transplantation Through an Indwelling Catheter in the Umbilical Vein
Islet transplantation is one of the effective and promising options for type 1 diabetes mellitus treatment1-4. The liver is the primary target location for infusion and portal vein catheterization is generally used.
- Trial name
- NCT02367534
- Testing
- umbilical vein catheterization
- Volunteers
- 12 people
- Sponsor
- Fuzhou General Hospital
Diabetes Mellitus, Type 1
Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment
Efficacy of pancreatic islet transplantation at 6 months compared to an intensive insulin therapy for 2 categories of patients: patients with unstable diabetes and patients who underwent kidney transplantation.
- Trial name
- TRIMECO (NCT01148680)
- Testing
- Islet Graft
- Where
- 9 sites in France, Switzerland
- Volunteers
- 50 people
- Sponsor
- University Hospital, Grenoble
Diabetes Mellitus, Type 1
Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control.
- Trial name
- NCT00434850
- Testing
- Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
LEA29Y (Belatacept) Emory Edmonton Protocol
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control.
- Trial name
- LEEP (NCT00468403)
- Testing
- Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab
- Where
- 2 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Pancreatitis
Carbon Monoxide-Saturated Medium for Islet Isolation
The goal of this study is to determine whether harvesting islets using carbon monoxide (CO)-saturated mediums can protect islet cell from death after autologous islet transplantation in patients with chronic pancreatitis.
- Trial name
- NCT02567240
- Testing
- Carbon monoxide-bubbled mediums
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Medical University of South Carolina
Type 1 Diabetes, Visual Impairment
Pancreatic Islet Transplantation to the Anterior Chamber of the Eye
This is a phase II prospective, interventional, open-labeled, proof-of-concept study. 2 years per participant, 2 years 6 months in total Total n=6 The primary objective is to assess the safety of human pancreatic islet…
- Trial name
- EYELETS (NCT04198350)
- Testing
- Islet implantation
- Where
- United Kingdom
- Sponsor
- Imperial College London
Islet Transplantation
Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy
The goal of this clinical trial is to learn if patients who have brittle type 1 diabetes receiving an islet transplantation will have better control of their sugars if they also receive one of 2 types of immune cells along with…
- Trial name
- NCT05973734
- Testing
- Infusion of recipient T regulatory cell, Infusion of concomitant Donor Derived Vertebral Bone Marrow
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Stanford University
Type 1 Diabetes Mellitus
A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation
The Cell Pouch™ is a novel implantable device, that is transplanted with therapeutic cells such as insulin producing islets. This combination product is designed for the treatment of Type 1 Diabetes Mellitus (T1D) with…
- Trial name
- NCT03513939
- Testing
- Sernova Cell Pouch
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sernova Biotherapeutics Inc.
Diabetes
Extending Indication for Islet Autotransplantation in Pancreatic Surgery
Islet autotransplantation (IAT) is a therapeutic approach used to prevent pancreatogenic diabetes or to reduce the severity of diabetes after a major pancreatectomy.
- Trial name
- AutoTx (NCT01702051)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Ospedale San Raffaele
Diabetes Mellitus
Clinical Study on the Safety and Efficacy of Immunophenotyped Pancreatic Endocrine Organoid Bank in Treating Patients With T3c Diabetes
Islet cells are isolated from resected pancreatic tissue obtained from patients undergoing surgery, followed by ex vivo expansion and culture.
- Trial name
- NCT06991829
- Testing
- HLA-matched pancreatic endocrine organoids transplantation
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Shanghai Zhongshan Hospital